Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05334940

Atopy Network - Comprehensive Allergy Centers: Medical Care of Patients With Moderate to Severe Allergic Diseases

The Atopy Registry aims to assess data about atopic disorders and their medical care in a standardized form. With this, the comparative efficacy, tolerability and safety of systemic therapies for atopic disorders should be investigated. An optional additional module "Bioanalytic" shall provide insights into further connections regarding immunology, genetics and microbiome.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

6 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The prevalence of atopic disorders increased in the western countries within the past decades. Atopic disorders are among others: food allergy, atopic dermatitis, allergic rhinitis, bronchial asthma, chronic spontaneous urticaria, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis.

Seriously affected patients often have coexisting atopic disorders. In fact, 60-75% of the patients with a severe atopic dermatitis also suffer from an allergic rhinoconjunctivitis and 40-50% from bronchial asthma. This leads to a decreased quality of life (LG) especially in seriously affected patients.

The treatment of atopic disorders is not standardized yet. The Atopy Registry should promote the creation of a Germany-wide registry for different atopic disorders.Furthermore, the registry should characterize the medical care of patients with atopic disorders (patient satisfaction, therapy order, treatment success). This study serves as a longterm observation und is designed to compare different systemic therapies, since head-to-head studies regarding the efficacy are still missing. The analysis of biomaterial is involved to state possible correlations between endotype and phenotype.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients are at least 6 years old
  • patients with a proven moderate to severe atopic disorder who are planned to receive a biologic systemic therapy
  • at least one additional proven atopic disorder

Exclusion criteria

  • <2 atopic disorders
  • poor compliance
  • pregnancy or breastfeeding

Treatment and study plan

not applicable, observational study

Other

Patients do not receive intervention

Primary outcomes

  1. Comorbidity Food Allergy

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Food Allergy: Food Allergy Quality of Life Questionnaire (FAQLQ) (type-dependent 23-30 items, score between 0 and 6; mean of scores, minimum = 0, maximum = 6; higher score = higher impact on quality of life)

  2. Comorbidity Atopic Dermatitis

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Atopic Dermatitis: Atopic Dermatitis-Control-Test (ADCT) (6 items, score between 0 and 4; sum, minimum = 0, maximum = 24; higher score = higher severity)

  3. Comorbidity Bronchial Asthma

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Bronchial Asthma: Asthma-Control-Test (ACT) (5 items, score between 0 and 5; sum, minimum = 0, maximum = 25; higher score = better disease control)

  4. Comorbidity Chronic rhinosinusitis with nasal polyps

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Chronic rhinosinusitis with nasal polyps: 22 Items Sino-Nasal Outcome Test (SNOT22) (22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)

  5. Comorbidity Chronic Spontaneous Urticaria

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Chronic Spointaneous Urticaria: Urticaria Control Test (UCT) (4 items, score between 0 and 5; sum, minimum = 0, maximum = 20; higher score = better control)

  6. Comorbidity Eosinophilic Esophagitis

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Eosinophilic Esophagitis: Dysphagia Symptoms Questionnaire (DSQ) (4 items, score between 0 and 4 but question-dependent; sum, minimum = 0, maximum = 10; higher score = higher impact)

  7. Comorbidity Allergic Rhinitis

    Time frame: 3 years

    Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:

    Allergic Rhinitis: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) (28 items, score between 0 and 6; mean, minimum = 0, maximum = 6; higher score = higher impact on quality of life)

Secondary outcomes

  1. Food Allergy Severity

    Time frame: 3 years

    Altered assessment of severity by investigation of oral thresholds and accidental reactions by oral food challenge.

  2. Atopic Dermatitis Severity

    Time frame: 3 years

    Altered assessment of severity and/or LQ using the Eczema Area and Severity Index (EASI).

    (Eczema Area and Severity; minimum = 0, maximum = 72; higher numbers = higher severity)

  3. Allergic Rhinitis Severity

    Time frame: 3 years

    Altered assessment of severity using the Total Nasal Symptom Score (TNSS). (Total Nasal Symptom Score; 3 items, score between 0 and 3; minimum = 0, maximum = 9; higher score = higher severity)

  4. Bronchial Asthma Severity FVC

    Time frame: 3 years

    Altered assessment of severity using the lung function parameter Forced Vital Capacity (FVC)

  5. Bronchial Asthma Severity FEV1

    Time frame: 3 years

    Altered assessment of severity using the lung function parameter Forced Expiratory Volume in 1 second (FEV1)

  6. Bronchial Asthma Severity FEF25-75

    Time frame: 3 years

    Altered assessment of severity using the lung function parameter Forced expiratory flow 25-75 (FEF25-75).

  7. Chronic Spontaneous Urticaria LQ (CUQ2oL)

    Time frame: 3 years

    Altered assessment of LQ using the Chronic Urticaria Questionnaire for Quality of Life (CUQ2oL).

    (Chronic Urticaria Questionnaire for Quality of Life; 23 items, score between 0 and 4; the score is calculated in percentage, minimum = 0%, maximum = 100%; higher percentage = lower quality of life)

  8. Chronic Spontaneous Urticaria Severity (AECT)

    Time frame: 3 years

    Altered assessment of severity using the Angioedema Control Test (AECT). (Angioedema Control Test; 4 items, score between 0 and 4; minimum = 0, maximum = 16; lower score = higher severity)

  9. Chronic Spontaneous Urticaria Severity (UAS7)

    Time frame: 3 years

    Altered assessment of severity and/or LQ using the 7-Days Urticaria Activity Score (UAS7).

    (7-Days Urticaria Activity Score; 2 items on 7 days, score between 0 and 3; minimum = 0, maximum = 42; higher score = higher severity)

  10. Eosinophilic Esophagitis Severity and/or LQ

    Time frame: 3 years

    Altered assessment of LQ using the Pediatric Quality of Life Inventory Eosinophilic Esophagitis (PedsQLEoE).

    (Pediatric Quality of Life Inventory Eosinophilic Esophagitis; 33 items, score between 0 and 4; scores are graded on an 0-100 scale in opposite order (0=100, 1=75, 2=50, 3=25, 4=0); minimum = 0, maximum = 100; higher mean score = higher quality of life

  11. Chronic Rhinosinusitis with Nasal Polyposis Severity

    Time frame: 3 years

    Altered assessment of severity using the Nasal Polyp Score. (Nasal Polyp Score; 2 items, score between 0 and 4; minimum = 0, maximum = 8; higher score = higher severity)

Study contacts

Contact information is provided by the study sponsor or research team.

Margitta Worm, Prof.

CONTACT

[email protected]

+49 30 450 518105

Philipp Globig, Dr.

CONTACT

[email protected]

+49 30 450 518409

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Registry information

Acronym: ATAC

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Apr 19, 2022
Registry last updated
Aug 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.